StockData

Cytokinetics vs Gyre Therapeutics

CYTK and GYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYTK and GYRE compare

Gyre Therapeutics is the larger company, worth 79 times as much as Cytokinetics ($508M against $6.4M).

Gyre Therapeutics grew revenue faster over the last twelve months (−3.7% versus −21.1% for Cytokinetics).

Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −1321% at Cytokinetics.

Gyre Therapeutics scores higher on the StockData Score (11 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYTKGYRE
Size and price
Market cap$6.4M$508M
Share price$51.65$4.56
Change, 1 year−22.3%−42.9%
Change, 5 years32.3%−75.7%
Beta (5Y)1.121.21
Employees673618
StockData Score
Total score411 (better)
Valuation score11
Growth score11
Performance score13 (better)
Health score16 (better)
Dividend score00
Valuation
P/S0.1× (better)4.7×
P/B–4.7×
FCF yield−9034%−1.5% (better)
Fair value–$5.29
Margin of safety–13.8%
Growth
Revenue growth (TTM)−21.1%−3.7% (better)
Revenue growth, 5Y average9.5%41.0% (better)
Net income growth (TTM)–−801%
Profitability
Gross margin–93.4%
Operating margin−1046%−14.4% (better)
Net margin−1321%−33.9% (better)
FCF margin−858%−7.2% (better)
Return on equity–−34.9%
Return on invested capital–−26.6%
Financial health
Debt / equity–0.00
Current ratio6.66 (better)4.32
Altman Z-score−3.378.53 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions115%7.8%
Held by insiders0.68%93.8%
Insider net buying, 12 months−$51.5M−$953K (better)
Short interest, % of float13.0%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.